FDA Approves First Functional Cure for Chronic Hepatitis B
The FDA has approved bepirovirsen as the first functional cure for chronic hepatitis B, offering a finite treatment course that maintains viral suppression…

The U.S. Food and Drug Administration (FDA) has approved bepirovirsen, marketed as Hibsago, for the treatment of chronic hepatitis B (CHB). This approval marks the introduction of the first therapy classified as a "functional cure," capable of suppressing the virus to undetectable levels in the blood even after the cessation of treatment.
Clinical data from two phase 3 trials demonstrated that a six-month course of the drug achieved a functional cure in 19 percent of participants, defined as maintaining undetectable viral levels for at least 24 weeks post-treatment. In contrast, the placebo group showed no such response. The drug is administered via weekly injections and may be used in conjunction with existing antiviral medications, which can be discontinued if the patient achieves the functional cure threshold.
Despite the clinical efficacy, the drug carries risks of serious side effects, specifically liver inflammation, necessitating regular monitoring through blood tests. Furthermore, the long-term durability of the cure beyond the 72-week study period remains unverified, and the treatment is most effective in patients who present with lower baseline levels of specific viral proteins.
This development shifts the standard of care from indefinite viral suppression to a finite treatment duration for a subset of the patient population. The manufacturer intends to expand global availability, while researchers continue to investigate combination therapies to improve the overall response rate. The approval addresses a significant public health burden, as CHB is a primary driver of global liver cancer cases.
More stories
- Dietitians advise small swaps for plant-based eating
- TikTok dementia videos mislead in 66.4% of sample, researchers say
- Aberdeen Royal Infirmary faces police inquiry call over 19 deaths
- Bariatric surgery group loses 28.2% after GLP-1 use
- TOFA boosts mouse energy use 18% while preserving muscle
- ICO probes NHS therapy notes accessible to up to 140,000 staff
- Energy drinks show 11-fold cardiac-arrest reporting signal
- Children with higher ultra-processed intake show stronger reward signals
- U.S. women report frequent fatigue at 20% rate
- CDC to aid Pennsylvania measles response after 1,222 cases
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Europe faces attribution gap after 16 cyber, physical incidents

